blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3873606

EP3873606 - BISPECIFIC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  06.08.2021
Database last updated on 22.05.2024
FormerThe international publication has been made
Status updated on  09.05.2020
Most recent event   Tooltip15.09.2023New entry: Renewal fee paid 
Applicant(s)For all designated states
MacroGenics, Inc.
9704 Medical Center Drive
Rockville, MD 20850 / US
For all designated states
NanoString Technologies, Inc.
530 Fairview Ave. North
Seattle, WA 98109 / US
For all designated states
Nottingham Trent University
50 Shakespeare Street
Nottingham NG1 4FQ / GB
[2021/36]
Inventor(s)01 / DAVIDSON, Jan, Kenneth
9704 Medical Center Drive
Rockville, MD 20850 / US
02 / CHURCH, Sara
6311 Rockefeller Ave.
Everett, WA 98203 / US
03 / RUTELLA, Sergio
50 Shakespeare Street
Nottingham NG1 4FQ / GB
 [2021/36]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2021/36]J A Kemp LLP
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date19878838.229.10.2019
[2021/36]
WO2019US58616
Priority number, dateUS201862752659P30.10.2018         Original published format: US 201862752659 P
US201862769078P19.11.2018         Original published format: US 201862769078 P
US201962878368P25.07.2019         Original published format: US 201962878368 P
[2021/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020092404
Date:07.05.2020
Language:EN
[2020/19]
Type: A1 Application with search report 
No.:EP3873606
Date:08.09.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 07.05.2020 takes the place of the publication of the European patent application.
[2021/36]
Search report(s)International search report - published on:US07.05.2020
(Supplementary) European search report - dispatched on:EP26.09.2022
ClassificationIPC:C07K16/28, A61P31/00, C07D417/14, A61K39/00, A61P35/00, C12Q1/68, C12Q1/6883
[2022/32]
CPC:
C07K16/2809 (EP,IL,KR,US); C07K16/2866 (EP,IL,KR,US); A61P31/00 (EP,IL);
A61P35/02 (KR,US); C12Q1/68 (EP,IL); C12Q1/6883 (EP,IL);
C12Q1/6886 (KR); A61K2039/505 (EP,IL,KR); A61K39/00 (EP,IL,KR,US);
C07K2317/24 (EP,IL); C07K2317/31 (EP,IL,KR,US); C07K2317/626 (EP,IL,KR);
C12Q2600/106 (EP,IL); C12Q2600/158 (EP,IL,KR) (-)
Former IPC [2021/36]A61P31/00, C07D417/14
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/36]
TitleGerman:BISPEZIFISCHE CD123 X CD3-DIABODIES ZUR BEHANDLUNG VON HÄMATOLOGISCHEN MALIGNOMEN[2021/36]
English:BISPECIFIC CD123 X CD3 DIABODIES FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES[2021/36]
French:DIACORPS BISPÉCIFIQUES CD123 X CD3 POUR LE TRAITEMENT DES TUMEURS MALIGNES HÉMATOLOGIQUES[2021/36]
Entry into regional phase20.05.2021National basic fee paid 
20.05.2021Search fee paid 
20.05.2021Designation fee(s) paid 
20.05.2021Examination fee paid 
Examination procedure20.05.2021Examination requested  [2021/36]
31.03.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
19.10.2021Renewal fee patent year 03
15.09.2022Renewal fee patent year 04
14.09.2023Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[IY]EP1612281  (VERIDEX LLC [US]) [I] 2-15 * See e.g. the abstract; claim 1; Example 6; Table 6a; Figure 12d; paragraphs [0132] and [0133] * [Y] 2-15;
 [XYI]WO2015026892  (MACROGENICS INC [US]) [X] 1,13,14 * See e.g. SEQ ID NOS: 9 and 17; paragraph [0242]; claim 12 * [Y] 1-15 [I] 15;
 [XPY]WO2019050521  (MACROGENICS INC [US]) [XP] 1,13-15 * SEQ ID NOs: 21 and 23; claims * [Y] 1-15;
 [XYI]  - AL-HUSSAINI MUNEERA ET AL, "Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 127, no. 1, doi:10.1182/BLOOD-2014-05-575704, ISSN 0006-4971, (20160107), pages 122 - 131, (20201023), XP086694301 [X] 1,13,14 * See e.g. the abstract; page 123, right column, second paragraph * [Y] 1-15 [I] 15

DOI:   http://dx.doi.org/10.1182/blood-2014-05-575704
 [T]  - Uy Geoffrey L ET AL, "Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia Michigan Medicine Bone Marrow Transplant", (20210211), pages 751 - 762, URL: https://watermark.silverchair.com/bloodbld2020007732.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAA8IwggO-BgkqhkiG9w0BBwagggOvMIIDqwIBADCCA6QGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMJKcOEGOmvtRnMa9HAgEQgIIDdel5apxzyhkCCpTO4NqJoo_3irzczeUwGjVFCT6W6mspTfbQ80DzP4VQ-SiHcuP_Q-_YKWZixo3QVr6Ha, (20210518), XP055805199 [T] 1-15 * the whole document *
 [IDY]  - VADAKEKOLATHU JAYAKUMAR ET AL, "Immune Gene Expression Profiling in Children and Adults with Acute Myeloid Leukemia Identifies Distinct Phenotypic Patterns", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20171208), vol. 130, doi:10.1182/BLOOD.V130.SUPPL_1.3942.3942, ISSN 0006-4971, page 3942, XP086630851 [ID] 2-15 * See e.g. the entire page 3; page 3, lines 3-6 * [Y] 2-15

DOI:   http://dx.doi.org/10.1182/blood.V130.Suppl_1.3942.3942
International search[A]US2011123442  (MUKHERJEE PINKU [US]) [A] 1, 2, 4/2 and 5/2* , entire document *;
 [Y]WO2015069935  (SLOAN KETTERING INST CANCER [US]) [Y] 4/2 and 5/2 * , entire document esp para [00137]-[00139] *;
 [A]US2017183413  (GALETTO ROMAN [FR]) [A] 1, 2, 4/2 and 5/2 * , entire document *;
 [XY]WO2017214092  (MACROGENICS INC [US]) [X] 1, 2 * , entire document esp para [0003], [00381], [00423], [00438] * [Y] 4/2 and 5/2
by applicant   - "NCBI", Database accession no. NM_000619.2
    - SAMARAJIWAL, S.A. et al., "INTERFEROME: The Database Of Interferon Regulated Genes", Nucleic Acids Research, (20090000), vol. 37, pages D852 - D857
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.